# Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.

> **NCT06393348** · PHASE2 · COMPLETED · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 155 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** HRS-7535
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06393348
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-17
- **Primary completion:** 2024-11-15
- **Final completion:** 2025-03-13
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06393348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06393348, "Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06393348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*